Biogen | BIIB - Des Atouts

Prix De L'Action
183.52
Variation Quotidienne
0.26 0.14%
Mensuellement
-5.47%
Annuel
28.25%
Q1 Prévisions
176.07




Des Atouts Changement Date
AbbVie USD 133.96B 62M 2025-12
Acadia Pharmaceuticals USD 1.56B 233.42M 2025-12
ALKERMES USD 2.49B 157.48M 2025-12
Amgen USD 90.59B 445M 2025-12
Bayer EUR 104.54B 331M 2025-12
Biogen USD 29.44B 232M 2025-12
BioMarin Pharmaceutical USD 7.59B 20.85M 2025-12
Bristol-Myers Squibb USD 96.89B 2.21B 2025-09
Eli Lilly USD 112.48B 2.46B 2025-12
Esperion Therapeutics USD 465.89M 101.87M 2025-12
Gilead Sciences USD 59.02B 490M 2025-12
Incyte USD 6.96B 627.62M 2025-12
Merck USD 129.55B 12.02B 2025-09
Moderna USD 12.34B 203M 2025-12
Neurocrine Biosciences USD 4.63B 365.8M 2025-12
Novartis USD 107.29B 2.89B 2025-09
Pfizer USD 208.73B 2.64B 2025-09
PTC Therapeutics USD 2.9B 255.07M 2025-12
Puma Biotechnology USD 202.86M 7.95M 2025-09
Regeneron Pharmaceuticals USD 40.56B 389.3M 2025-12
Sangamo BioSciences USD 97.56M 11.39M 2025-06
Sanofi EUR 126.81B 2.99B 2025-12
Sanofi EUR 126.81B 25.48B 2025-12
Sarepta Therapeutics USD 3.35B 143.73M 2025-12
Teva Pharmaceutical Industries USD 40.75B 892M 2025-12
Ultragenyx Pharmaceutical USD 1.53B 341.56M 2025-12
United Therapeutics USD 7.88B 528.9M 2025-12
Vertex Pharmaceuticals USD 25.64B 780.7M 2025-12